Barton Crockett, FBR Capital Markets, weighs in on Disney's charmed quarter and Rupert Murdoch's surprise announcement to withdraw 21st Century Fox's bid for Time Warner.
CNBC's David Faber shares his thoughts on the Rupert Murdoch's surprising decision to withdraw 21st Century Fox's bid for Time Warner.
CNBC's David Faber weighs in on Sprint's move to abandon its bid to buy T-Mobile. Faber says the deal was about regulatory impediments.
Rich Greenfield, BTIG analyst, provides his thoughts on the fallout from shareholders after Rupert Murdoch withdrew his bid for Time Warner.
Gerald Levin, former Time Warner chairman & CEO, shares his thought on 21st Century's decision to drop its bid for Time Warner. I don't think it's a "head shake," says Levin. There's a lot more work to be done to properly valuate Time Warner.
Allergan sued Valeant Pharmaceuticals and Pershing Square Capital, alleging both acted inappropriately in their hostile $53 billion bid.
CNBC's Carl Quintanilla reports shares of T-Mobile and Sprint have been halted on news France's Iliad made a buyout offer for T-Mobile.
He has a very simple model which is to create shareholder value, says Steve MacMillan, Hologic president & CEO, discussing Icahn's stake in Hologic. He's clearly not a micromanager, says MacMillian.
Steve MacMillan, Hologic president & CEO, discusses the company's progress in developing 3D imaging technology. The benefit of this is you can catch the big stuff early, says MacMillian.
Board representation could appear in a revised proposal, according to a report from Bloomberg.
Herb Greenberg, CNBC contributor, shares his thoughts on Bill Ackman's comments that Herbalife is a fraud. Let's not forget this is about the business model, says Greenberg.
Pershing Square's Bill Ackman says he'll show evidence that Herbalife is a massive fraud.
Bill Ackman, Pershing Square, explains why he is not upping his bid for Allergan. The market clearly thinks the chance of Valeant buying Allergan has gone up, says Ackman.
CNBC's Meg Tirrell reports Allergan posted Q2 results that beat on earnings and sales, as the company announced its restructuring plans, which may include an acquisition of its own.
Some of the names on the move ahead of the open.
Valeant has complained to regulators that claims made by Allergan to counter a hostile takeover are misleading, sources have told CNBC.
CNBC's Julia Boorstin provides insight to the reaction in shares of cable companies after a $80 billion takeover offer from 21st Century Fox for Time Warner was rejected.
CNBC's Andrew Ross Sorkin provides insight to the $80 billion takeover offer from 21st Century Fox for Time Warner, which was rejected.
CNBC's David Faber discusses Bill Ackman's backing of Valeant's takeover bid for Allergan. Allergan CEO David Pyott has bone to pick with Ackman.
CNBC's David Faber provides insight to AbbVie's $46 billion case to take over Shire.